Literature DB >> 22381641

Head and neck basal cell carcinoma prevalence in individuals submitted to childhood X-ray epilation for tinea capitis treatment.

Paula Boaventura1, Rosa Oliveira, Dina Pereira, Paula Soares, José Teixeira-Gomes.   

Abstract

BACKGROUND: A higher prevalence for basal cell carcinoma (BCC) has been associated with radiation, namely with tinea capitis epilation treatment.
OBJECTIVE: To evaluate the prevalence of head and neck basal cell carcinoma (BCC) and to identify the major risk factors for BCC in individuals irradiated in childhood for tinea capitis treatment.
METHODS: We clinically observed 1,308 individuals from an original cohort of 5,356 irradiated between 1950 and 1963, registering previous skin lesions excisions and proposing for surgery all the suspicious lesions detected. In 585 participants, 47 with BCC, the skin pigmentation was measured.
RESULTS: The overall prevalence of BCC was 8.0% and of multiple BCC was 2.4%. Both total (14.7%) and multiple BCC (6.6%) were significantly more common in the individuals who had received a higher radiation dose. Multiple BCC was more prevalent (3.7%) in younger irradiated individuals and total BCC (9.4%) in women. Participants with BCC and without BCC presented similar skin pigmentation.
CONCLUSION: Younger age at irradiation, higher dose and female gender increased the risk of developing BCC in these irradiated individuals.

Entities:  

Mesh:

Year:  2012        PMID: 22381641     DOI: 10.1684/ejd.2012.1670

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  7 in total

1.  EURADOS strategic research agenda: vision for dosimetry of ionising radiation.

Authors:  W Rühm; E Fantuzzi; R Harrison; H Schuhmacher; F Vanhavere; J Alves; J F Bottollier Depois; P Fattibene; Ž Knežević; M A Lopez; S Mayer; S Miljanić; S Neumaier; P Olko; H Stadtmann; R Tanner; C Woda
Journal:  Radiat Prot Dosimetry       Date:  2015-03-09       Impact factor: 0.972

2.  Thyroid and parathyroid tumours in patients submitted to X-ray scalp epilation during the tinea capitis eradication campaign in the North of Portugal (1950-1963).

Authors:  Paula Boaventura; Dina Pereira; Adélia Mendes; José Teixeira-Gomes; Manuel Sobrinho-Simões; Paula Soares
Journal:  Virchows Arch       Date:  2014-08-22       Impact factor: 4.064

Review 3.  Radiotherapy for benign disease; assessing the risk of radiation-induced cancer following exposure to intermediate dose radiation.

Authors:  Stephanie R McKeown; Paul Hatfield; Robin J D Prestwich; Richard E Shaffer; Roger E Taylor
Journal:  Br J Radiol       Date:  2015-10-14       Impact factor: 3.039

4.  Nonmelanoma Skin Cancer in Childhood and Young Adult Cancer Survivors Previously Treated With Radiotherapy.

Authors:  Stefanie L Thorsness; Azael Freites-Martinez; Michael A Marchetti; Cristian Navarrete-Dechent; Mario E Lacouture; Emily S Tonorezos
Journal:  J Natl Compr Canc Netw       Date:  2019-03-01       Impact factor: 11.908

5.  Cancer incidence after childhood irradiation for tinea capitis in a Portuguese cohort.

Authors:  Luís Antunes; Maria José Bento; Manuel Sobrinho-Simões; Paula Soares; Paula Boaventura
Journal:  Br J Radiol       Date:  2019-11-11       Impact factor: 3.039

6.  IL6-174 G>C Polymorphism (rs1800795) Association with Late Effects of Low Dose Radiation Exposure in the Portuguese Tinea Capitis Cohort.

Authors:  Paula Boaventura; Cecília Durães; Adélia Mendes; Natália Rios Costa; Inês Chora; Sara Ferreira; Emanuel Araújo; Pedro Lopes; Gilberto Rosa; Pedro Marques; Paulo Bettencourt; Inês Oliveira; Francisco Costa; Isabel Ramos; Maria José Teles; João Tiago Guimarães; Manuel Sobrinho-Simões; Paula Soares
Journal:  PLoS One       Date:  2016-09-23       Impact factor: 3.240

Review 7.  Head and neck cutaneous basal cell carcinoma: what should the otorhinolaryngology head and neck surgeon care about?

Authors:  António Castanheira; Paula Boaventura; Manuel Pais Clemente; Paula Soares; Alberto Mota; José Manuel Lopes
Journal:  Acta Otorhinolaryngol Ital       Date:  2019-07-31       Impact factor: 2.124

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.